GLP-1 Cost With Medicare in 2026: The $50 Bridge Program Explained
Price verification — October 26, 2026
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
- Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
- Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
- Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
- Sesame annual-commitment terms: Official source.
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due.
Key Takeaways
- The Medicare GLP-1 Bridge launched July 1, 2026 and runs through December 31, 2027
- Flat copay of $50/month for all covered GLP-1 medications, all dose strengths
- Covers Wegovy (pen + pill), Zepbound KwikPen, and Foundayo
- Three eligibility groups based on BMI + comorbidities
- The $50 copay does not count toward your annual deductible or out-of-pocket maximum
The Medicare GLP-1 Bridge is the biggest single policy change for GLP-1 affordability in 2026. For the first time, Medicare Part D beneficiaries can access FDA-approved GLP-1 weight loss medications at a flat $50/month copay — regardless of dose strength. Before this program, Medicare generally excluded weight-loss medications from Part D coverage.
Here's everything you need to know about eligibility, covered drugs, how claims work, and what the program means for your out-of-pocket costs.
What's Covered
| Medication | Format | Bridge Copay | Covered? |
|---|---|---|---|
| Wegovy (semaglutide) | Injectable pen — all doses | $50/mo | ✓ Yes |
| Wegovy (semaglutide) | Daily oral tablet — all doses | $50/mo | ✓ Yes |
| Zepbound (tirzepatide) | KwikPen multi-dose — all doses | $50/mo | ✓ Yes |
| Foundayo (orforglipron) | Oral tablet — all doses | $50/mo | ✓ Yes |
| Zepbound | Single-dose vials | — | ✗ Excluded |
| Zepbound | Single-dose pens | — | ✗ Excluded |
| Ozempic | Any format (diabetes only) | — | Not via Bridge* |
| Compounded GLP-1s | Any | — | ✗ Excluded |
*Ozempic may be covered under standard Part D for type 2 diabetes, but not through the GLP-1 Bridge weight-loss program.
Eligibility: Three Groups
To qualify, you must be enrolled in an eligible Medicare Part D plan (standalone PDP or MA-PD) in 2026 and meet one of three clinical criteria groups:
Group 1 — BMI ≥ 35
No additional conditions required. If your BMI is 35 or above at the time your prescriber initiates therapy, you qualify. This is the broadest eligibility tier.
Group 2 — BMI 30 to 34.99
Must have at least one documented weight-related comorbidity, such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Your physician must verify these conditions at the time therapy is initiated.
Group 3 — BMI 27 to 29.99
Must have at least one of four specific conditions: prediabetes, history of stroke, history of heart attack, or symptomatic peripheral artery disease (PAD). This is the narrowest eligibility group.
How the Claim Process Works
The Bridge uses a "deliberate initial rejection" process that sounds unusual but is straightforward in practice:
- Your doctor submits a prior authorization and prescribes the covered GLP-1 medication
- Your pharmacy submits the claim to your standard Part D plan
- The Part D plan returns a structured rejection code (this is intentional, not an error)
- That rejection automatically triggers the Bridge Program processor
- The Bridge processor approves the claim at the $50 copay
- You pay $50 at the pharmacy counter
From your perspective, you show up, hand over your prescription, and pay $50. The pharmacy handles the claim routing behind the scenes.
The $50/month is a flat copay regardless of the medication's list price. It does not count toward your Part D annual deductible, and it does not apply to your out-of-pocket maximum. This is by design — the Bridge is a standalone payment pathway that runs parallel to your regular Part D benefits.
What If You Don't Qualify?
If your BMI falls below the eligibility thresholds, or if you're in a Medicare plan type that isn't eligible, you have other options:
Injectable
Compounded medications are prepared by pharmacies and are not FDA-approved. They have not been evaluated for safety, efficacy, or manufacturing quality by the FDA.
Check Current Pricing →Paid link · We may earn a commission
Injectable semaglutide
Compounded medications are prepared by pharmacies and are not FDA-approved. They have not been evaluated for safety, efficacy, or manufacturing quality by the FDA.
Paid link · We may earn a commission
Brand-name only (Wegovy, Zepbound, Foundayo)
Check Current Pricing →Paid link · We may earn a commission
The Medicare GLP-1 Bridge at $50/month is the most affordable legal pathway to FDA-approved GLP-1 medications in 2026 — period. If you're a Medicare Part D beneficiary with a BMI of 27+ and qualifying conditions (or 35+ with no conditions needed), this program should be your first step. Ask your doctor about eligibility, get the prior authorization submitted, and take your prescription to a participating pharmacy. The program runs through December 2027.
Medicare GLP-1 Bridge information based on CMS program guidelines as of July 1, 2026 launch. Eligibility and covered formulations may be updated — confirm with your Part D plan or CMS.gov.